Navigation Links
Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
Date:4/1/2008

Leading Expert Discusses Study During Late-Breaking Presentations at ACC

CHICAGO, April 1, 2008 /PRNewswire-FirstCall/ -- Bioheart, Inc. (Nasdaq: BHRT) announced today that final six-month, follow-up patient data was presented today during the late-breaking clinical trial sessions at the American College of Cardiology, suggesting that MyoCell(R) myoblast clinical cell therapy is a safe and potentially effective alternative treatment to standard medical therapy alone for improving heart function among patients with previously implanted cardiac devices who are experiencing congestive heart failure.

The findings from the SEISMIC(1) Trial, a 40-patient, randomized, multicenter, controlled, Phase II-a study conducted in Europe, evaluated MyoCell myoblast clinical cell therapy delivered via the MyoCath(R), endoventricular needle-injection catheter in patients previously fitted with implanted cardiac defibrillators(ICDs), receiving standard medical therapy and who are experiencing congestive heart failure. On admission to the trial, patients were randomized on a two-to-one ratio into the treatment versus control groups with 26 patients receiving MyoCell therapy and 14 patients in the control group. All patients were experiencing congestive heart failure and were previously fitted with ICDs and receiving standard medical therapy. Both the MyoCell biologic therapy and the MyoCath needle-injection catheter, developed by Bioheart, Inc., are currently being studied as investigational products.

"The results from the SEISMIC Trial are encouraging," said Prof. Patrick W. Serruys, MD, PhD, Principal Investigator and Chief, Department of Interventional Cardiology, Thoraxcenter, Erasmus Medical Center - Rotterdam, the Netherlands. "While
'/>"/>

SOURCE Bioheart, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Final Data From the SEISMIC Trial Suggest Safety, Efficacy of Autologous Stem- Cell Therapy for Treating Congestive Heart Failure
2. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
3. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
4. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
5. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
6. Hope for Emphysema Sufferers: Clinical Trial That May Help Patients Breathe Easier Begins at Central DuPage Hospital
7. TAXUS(R) Stent Demonstrates Similar Outcomes in Diabetic Patients Compared to Non-diabetics in Pooled Analysis of TAXUS IV and V Trials
8. Major Deficiencies in Design; Funding of Clinical Trials Affects Future of Scientific Innovation
9. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
10. CVBT Appoints Dr. Nabil Dib as Principal Investigator for Phase II Heart Trial
11. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014 Research ... "Global Respiratory Devices Market 2014-2018" report to ... A respiratory device is a medical device ... is having difficulty in breathing and cannot achieve adequate ... such as cystic fibrosis, asthma, COPD, and ARDS require ...
(Date:7/29/2014)... Ill. , July 29, 2014  Sysmex America, ... and information systems technology, will feature an exhibit booth ... Annual Meeting and Clinical Lab Expo in ... 2014. "We are extremely excited to ... opportunity to interact with our customers and continue the ...
(Date:7/29/2014)... Calif. , July 29, 2014  Based ... response systems (PERS) market, Frost & Sullivan recognizes ... Sullivan Award for Price Performance Value Leadership. MobileHelp,s ... directly captures expectations for tech progression in personal ... consumers for these solutions. MobileHelp is ...
Breaking Medicine Technology:Global Respiratory Devices Market 2014-2018 2New Product Offerings Highlight Sysmex's Presence at 2014 AACC in Chicago 2New Product Offerings Highlight Sysmex's Presence at 2014 AACC in Chicago 3Frost & Sullivan Applauds MobileHelp for its Targeted Supplies for the PERS Market 2Frost & Sullivan Applauds MobileHelp for its Targeted Supplies for the PERS Market 3
... America, Inc. (SAI), a leading medical diagnostic instrument ... Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: ... for Sysmex America, Inc. to provide fully automated ... of the systems has been completed.   ...
... Medical Systems (NYSE: VAR ) will hold an ... of  the American Society for Therapeutic Radiology and Oncology (ASTRO) ... are invited to join senior management for a review of ... at ASTRO. Varian will host a meeting with ...
Cached Medicine Technology:Sysmex America Announces LabCorp Hematology Automation Agreement 2Varian Medical Systems Schedules Investor Meeting and Fiscal Year End Review at ASTRO in San Diego, November 2, 2010 2
(Date:7/29/2014)... July 29, 2014 CRN International has ... Services Operation. , Christina Upton, an 11-year veteran at ... Client Services responsible for managing the day-to-day execution of ... at the center of all activities for CRN clients, ... in the world . The department interfaces directly with ...
(Date:7/29/2014)... Foot Levelers Chairman and CEO Kent ... Chiropractic Association (FCA) National Convention and Expo, speaking on ... Chain Changes on Thursday, August 20th at the Hyatt ... the positive impact functional foot orthotics, like Foot Levelers ... pain, plantar fasciitis, and hammertoes. , Invented by a ...
(Date:7/29/2014)... Healthcare staffing agency Medical Solutions ... Tomorrow Scholarship Competition winners:, ,     Alonso ...     Racheal D., Freshman, Cerritos College in Norwalk, ... College in Houston, TX , Each ... hosts the Nurses of Tomorrow Scholarship competition as ...
(Date:7/29/2014)... Dallas, Texas (PRWEB) July 29, 2014 ... the Global Biosimilars Market report is an essential ... biosimilars industry. Using detailed company data, financial analysis, ... in-depth analysis of the current and future growth ... the various regulatory frameworks under which biosimilars are ...
(Date:7/29/2014)... 1WorldSync announces B. Braun Melsungen ... will utilize the Global Data Synchronization Network™ (GDSN®) ... share product information with the U.S. Food and ... their global supply chain. Holger Clobes, Head of ... "B. Braun serves customers in 61 countries, among ...
Breaking Medicine News(10 mins):Health News:CRN International Names New Director to Lead Client Services Department 2Health News:Foot Levelers CEO Kent Greenawalt Speaking at FCA Convention 2Health News:Medical Solutions Announces Nurses of Tomorrow Scholarship Winners 2Health News:World Biosimilars Market Value Exceed $262 Billion by 2019 Says a New Report Available at MarketOptimizer.org 2Health News:World Biosimilars Market Value Exceed $262 Billion by 2019 Says a New Report Available at MarketOptimizer.org 3Health News:World Biosimilars Market Value Exceed $262 Billion by 2019 Says a New Report Available at MarketOptimizer.org 4Health News:B. Braun Selects 1WorldSync Unique Device Identification and Product Information Solution 2Health News:B. Braun Selects 1WorldSync Unique Device Identification and Product Information Solution 3
... recommendations for the diagnosis and subsequent treatment of superior ... the New England Journal of Medicine. ,The ... vena cava syndrome, provides clinical management evidence, and presents ... Lynn D. Wilson, M.D., MPH, Professor, Clinical Director, and ...
... need medical care in Korea but can afford it ... health services, according to a Yale School of ... Health. ,Low-income individuals with multiple chronic ... restrictions because they need and use more services, said ...
... to create therapies or simply investigate how organisms develop, ... of biological science's toughest assignments: keeping their tiny research ... notoriously finicky tastes, and despite a decade of advances, ... cells will continue dividing indefinitely in culture or begin ...
... needed to determine the true effects of low to ... impact on pregnant women of different policies on ... ,Recommendations for safe levels of drinking during ... organisations in Australia, according to new report written by ...
... of yoghurt could contain the cure for certain types ... . ,Overuse of antibiotics has led ... vancomycin-resistant enterococci (VRE), which are responsible for persistent and ... commercial yoghurts, may have a beneficial effect on human ...
... deceased older donors on a pump as opposed to ... cooler may lower hospital costs, improve initial organ ... according to new research by Wake Forest University Baptist Medical ... preservation times can be safely extended to permit more time ...
Cached Medicine News:Health News:Clinical Approach Defined for Superior Vena Cava Syndrome 2Health News:Poor and Chronically Ill in Korea Pay More for Healthcare 2Health News:New Technique Dissects Stem Cells' Picky Likes, Dislikes 2Health News:New Technique Dissects Stem Cells' Picky Likes, Dislikes 3Health News:Better Research Needed On Alcohol In Pregnancy 2Health News:Preserving Kidneys on a Pump May Promote More Organ Sharing 2
100L...
... A fixed pipette is ideal ... single volume. Fixed volume FInnpipettes ... advantages as other Finnpipette Digital ... Super blow-out (1-40ul), Soft-touch tip ...
This fixed-volume digital micropipet is used to accurately measure and transfer 20 microliters of solution....
Pipetman F is a fixed-volume, air-displacement pipette. Thirteen robust models cover a large volume range from 2 L to 1000 L, with Gilsons legendary accuracy and precision....
Medicine Products: